ABSTRACT
BACKGROUND: Parkinson's disease is a progressive neurodegenerative disorder that results in the widespread loss of select classes of neurons throughout the nervous system. The pathological hallmarks of Parkinson's disease are Lewy bodies and neurites, of which α-synuclein fibrils are the major component. α-Synuclein aggregation has been reported in the gut of Parkinson's disease patients, even up to a decade before motor symptoms, and similar observations have been made in animal models of disease. However, unlike the central nervous system, the nature of α-synuclein species that form these aggregates and the classes of neurons affected in the gut are unclear. We have previously reported selective expression of α-synuclein in cholinergic neurons in the gut (J Comp Neurol. 2013; 521:657), suggesting they may be particularly vulnerable to degeneration in Parkinson's disease. METHODS: In this study, we used immunohistochemistry to detect α-synuclein oligomers and fibrils via conformation-specific antibodies after rotenone treatment or prolonged exposure to high [K+ ] in ex vivo segments of guinea-pig ileum maintained in organotypic culture. KEY RESULTS: Rotenone and prolonged raising of [K+ ] caused accumulation of α-synuclein fibrils in the axons of cholinergic enteric neurons. This took place in a time- and, in the case of rotenone, concentration-dependent manner. Rotenone also caused selective necrosis, indicated by increased cellular autofluorescence, of cholinergic enteric neurons, labeled by ChAT-immunoreactivity, also in a concentration-dependent manner. CONCLUSIONS & INFERENCES: To our knowledge, this is the first report of rotenone causing selective loss of a neurochemical class in the enteric nervous system. Cholinergic enteric neurons may be particularly susceptible to Lewy pathology and degeneration in Parkinson's disease.
Subject(s)
Axons/chemistry , Cholinergic Neurons/chemistry , Enteric Nervous System/chemistry , Potassium/pharmacology , Rotenone/pharmacology , alpha-Synuclein/analysis , Animals , Axons/drug effects , Axons/pathology , Cholinergic Neurons/drug effects , Cholinergic Neurons/pathology , Enteric Nervous System/drug effects , Enteric Nervous System/pathology , Extracellular Fluid/chemistry , Extracellular Fluid/drug effects , Female , Guinea Pigs , Insecticides/pharmacology , Male , Organ Culture TechniquesABSTRACT
Parkinson's disease (PD) is a neurodegenerative disease resulting from progressive loss of dopaminergic nigrostriatal neurons. α-Synuclein protein conformational changes, resulting in cytotoxic/aggregated proteins, have been linked to PD pathogenesis. We investigated a unilateral rotenone-lesioned mouse PD model. Unilateral lesion of the medial forebrain bundle for two groups of male C57 black mice (n=5); adult (6-12 months) group and aged (1.75-2 years) group, was via stereotactic rotenone injection. After 2 weeks post-lesion, phenotypic Parkinsonian symptoms, resting tremor, postural instability, left-handed bias, ipsiversive rotation and bradykinesia were observed and were more severe in the aged group. We investigated protein expression profiles of the post-translational modifier, SUMO-1, and α-synuclein between the treated and control hemisphere, and between adult and aged groups. Western analysis of the brain homogenates indicated that there were statistically significant (p<0.05) increases in several specific molecular weight species (ranging 12-190 kDa) of both SUMO-1 (0.75-4.3-fold increased) and α-synuclein (1.6-19-fold increase) in the lesioned compared to un-lesioned hemisphere, with the adult mice showing proportionately greater increases in SUMO-1 than the aged group.
Subject(s)
Aging/metabolism , Brain/metabolism , Disease Models, Animal , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/metabolism , Rotenone , SUMO-1 Protein/metabolism , alpha-Synuclein/metabolism , Animals , Humans , Male , Mice , Mice, Inbred C57BL , Up-RegulationABSTRACT
Multiple system atrophy (MSA) is an adult-onset neurodegenerative disease characterised by Parkinsonian and autonomic symptoms and by widespread intracytoplasmic inclusion bodies in oligodendrocytes. These glial cytoplasmic inclusions (GCIs) are comprised of 9-10 nm filaments rich in the protein alpha-synuclein, also found in neuronal inclusion bodies associated with Parkinson's disease. Metallothioneins (MTs) are a class of low-molecular weight (6-7 kDa), cysteine-rich metal-binding proteins the expression of which is induced by heavy metals, glucocorticoids, cytokines and oxidative stress. Recent studies have shown a role for the ubiquitously expressed MT-I/II isoforms in the brain following a variety of stresses, whereas, the function of the brain-specific MT isoform, MT-III, is less clear. MT-III and MT-I/II immunostaining of post-mortem tissue in MSA and normal control human brains showed that the number of MT-III-positive cells is significantly increased in MSA in visual cortex, whereas MT-I/II isoforms showed no significant difference in the distribution of immunopositive cells in MSA compared to normal tissue. GCIs were immunopositive for MT-III, but were immunonegative for the MT-I/II isoforms. Immunofluorescence double labelling showed the co-localisation of alpha-synuclein and MT-III in GCIs in MSA tissue. In isolated GCIs, transmission electron microscopy demonstrated MT-III immunogold labelling of the amorphous material surrounding alpha-synuclein filaments in GCIs. High-molecular weight MT-III species in addition to MT-III monomer were detected in GCIs by Western analysis of the detergent-solubilised proteins of purified GCIs. These results show that MT-III, but not MT-I/II, is a specific component of GCIs, present in abnormal aggregated forms external to the alpha-synuclein filaments.
Subject(s)
Inclusion Bodies/metabolism , Multiple System Atrophy/metabolism , Nerve Tissue Proteins/metabolism , Oligodendroglia/metabolism , Aged , Aged, 80 and over , Humans , Inclusion Bodies/pathology , Metallothionein 3 , Middle Aged , Multiple System Atrophy/pathology , Nerve Tissue Proteins/biosynthesis , Neuroglia/metabolism , Neuroglia/pathology , Oligodendroglia/pathology , Up-Regulation/physiologyABSTRACT
Gamma-aminobutyric acid(A) (GABA(A)) receptors (GABA(A)R) are inhibitory heteropentameric chloride ion channels comprising a variety of subunits and are localized at postsynaptic sites within the central nervous system. In this study we present the first detailed immunohistochemical investigation on the regional, cellular, and subcellular localisation of alpha(1), alpha(2), alpha(3), beta(2,3), and gamma(2) subunits of the GABA(A)R in the human substantia nigra (SN). The SN comprises two major regions, the SN pars compacta (SNc) consisting of dopaminergic projection neurons, and the SN pars reticulata (SNr) consisting of GABAergic parvalbumin-positive projection neurons. The results of our single- and double-labeling studies demonstrate that in the SNr GABA(A) receptors contain alpha(1), alpha(3), beta(2,3), and gamma(2) subunits and are localized in a weblike network over the cell soma, dendrites, and spines of SNr parvalbumin-positive nonpigmented neurons. By contrast, GABA(A)Rs on the SNc dopaminergic pigmented neurons contain predominantly alpha(3) and gamma(2) subunits; however there is GABA(A)R heterogeneity in the SNc, with a small subpopulation (6.5%) of pigmented SNc neurons additionally containing alpha(1) and beta(2,3) GABA(A)R subunits. Also, in the SNr, parvalbumin-positive terminals are adjacent to GABA(A)R on the soma and proximal dendrites of SNr neurons, whereas linear arrangements of substance P-positive terminals are adjacent to GABA(A) receptors on all regions of the dendritic tree. These results show marked GABA(A)R subunit hetereogeneity in the SN, suggesting that GABA exerts quite different effects on pars compacta and pars reticulata neurons in the human SN via GABA(A) receptors of different subunit configurations.
Subject(s)
Neurons/metabolism , Receptors, GABA-A/metabolism , Substantia Nigra/metabolism , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Neurons/classification , Neurons/cytology , Parvalbumins/metabolism , Postmortem Changes , Protein Subunits/metabolism , Substance P/metabolism , Tyrosine 3-Monooxygenase/metabolismABSTRACT
Chronic oxidative stress has been linked to the neurodegenerative changes characteristic of Parkinson's disease, particularly alpha-synuclein accumulation and aggregation. However, it remains contentious whether these alpha-synuclein changes are cytotoxic or neuroprotective. The current study utilised long-term primary neural culture techniques with antioxidant free media to study the cellular response to chronic oxidative stress. Cells maintained in antioxidant free media were exquisitely more vulnerable to acute exposure to hydrogen peroxide, yet exposure of up to 10 days in antioxidant free media did not lead to morphological alterations in neurones or glia. However, a subpopulation of neurones demonstrated a significant increase in the level of alpha-synuclein expressed within the cell body and at synaptic sites. This subset of neurones was also more resistant to apoptotic changes following exposure to antioxidant free media relative to other neurones. These data indicate that increased alpha-synuclein content is associated with neuroprotection from relatively low levels of oxidative stress.
Subject(s)
Neurons/metabolism , Oxidative Stress/physiology , Up-Regulation/physiology , alpha-Synuclein/metabolism , Animals , Cell Count/methods , Cerebral Cortex/cytology , Culture Media, Conditioned/pharmacology , Diagnostic Imaging/methods , Docosahexaenoic Acids/administration & dosage , Glial Fibrillary Acidic Protein/metabolism , Hydrogen Peroxide/adverse effects , Immunohistochemistry/methods , Microtubule-Associated Proteins/metabolism , Neurons/drug effects , Oxidants/adverse effects , Oxidative Stress/drug effects , R-SNARE Proteins/metabolism , Time Factors , Up-Regulation/drug effectsABSTRACT
Conjugation of the small ubiquitin-like modifier, SUMO-1, to target proteins is linked to the regulation of multiple cellular pathways, including nucleocytoplasmic trafficking, cell cycle progression, the ubiquitin-proteasome system and apoptosis. Recently, the accumulation of SUMOylated proteins in pathological neuronal intranuclear aggregates has been found in several neurodegenerative diseases. The aim of our study was to examine SUMO-1 in the alpha-synucleinopathy diseases, Multiple System Atrophy (MSA) and Dementia with Lewy Bodies (DLB). We conducted anti-SUMO-1 immunostaining of fixed brain tissue sections and smears of unfixed brain tissue homogenates of DLB and MSA cases. We found that oligodendroglial cytoplasmic inclusions, the alpha-synuclein-positive cytoplasmic aggregates that characterize MSA, exhibit robust punctate SUMO-1 immunostaining, marking discrete submicron-sized subdomains within the inclusion bodies. Lewy bodies in smears of DLB tissue homogenates showed similar SUMO-1-positive structures, although these were not detected in fixed tissue. In cell culture experiments, we found that the nuclear and perinuclear accumulation of SUMO-1 aggregates could be induced in glioma cells by chemical inhibition of proteasomal protein degradation.
Subject(s)
Cerebral Cortex/metabolism , Inclusion Bodies/metabolism , Lewy Body Disease/metabolism , Multiple System Atrophy/metabolism , Nerve Tissue Proteins/metabolism , Neuroglia/metabolism , SUMO-1 Protein/metabolism , Biomarkers/metabolism , Cytoplasm/metabolism , Humans , Synucleins , Tissue Distribution , alpha-SynucleinABSTRACT
Multiple system atrophy (MSA) is characterized by the formation of oligodendroglial cytoplasmic inclusions (GCIs) consisting of alpha-synuclein filaments. AlphaB-crystallin, a small chaperone protein that binds to unfolded proteins and inhibits aggregation, has been documented in GCIs. We investigated the relative abundance and speciation of alphaB-crystallin in GCIs in MSA brains. We also examined the influence of alphaB-crystallin on the formation of cytoplasmic inclusions in cultured glial cells. Immunohistochemistry and confocal microscopy revealed alphaB-crystallin is a prominent component of GCIs, more abundant than in Lewy bodies in Lewy body dementia. One- and two-dimensional gel electrophoresis and mass spectrometric analysis of GCIs immunopurified from MSA brains indicated that alphaB-crystallin is a major protein component with multiple post-translationally modified species. In cultured C6 glioma cells treated with the proteasomal inhibitor, lactacystin, to induce accumulation of ubiquitinated proteins, a subset of cells showed increased cytoplasmic staining for alphaB-crystallin. Proteasome-inhibited cells transfected with GFP-tagged alpha-synuclein resulted in ubiquitin- and alphaB-crystallin-positive aggregates resembling GCIs in MSA brains. Our results indicate that alphaB-crystallin is a major chaperone in MSA, and suggest a role of the protein in the formation of inclusion bodies in glial cells.
Subject(s)
Inclusion Bodies/metabolism , Multiple System Atrophy/metabolism , Neuroglia/metabolism , alpha-Crystallin B Chain/biosynthesis , Amino Acid Sequence , Animals , Humans , Inclusion Bodies/genetics , Inclusion Bodies/pathology , Molecular Sequence Data , Multiple System Atrophy/pathology , Neuroglia/pathology , Rats , Tumor Cells, Cultured , alpha-Crystallin B Chain/geneticsABSTRACT
Neuronal intranuclear inclusion disease (NIID) is a rare neurodegenerative disorder characterized by progressive ataxia and neuronal nuclear inclusions (NIs), similar to the inclusions found in expanded CAG repeat diseases. NIID may be familial or sporadic. The cause of familial NIID is poorly understood, as no CAG expansion has been detected. We examined three cases, from two unrelated families, who had autosomal dominant NIID but normal CAG repeats in genes involved in polyglutamine neurodegenerative diseases. We found that NIs in all three cases were intensely immunopositive for SUMO-1, a protein which covalently conjugates to other proteins and targets them to the nuclear regions (nuclear bodies) responsible for nuclear proteasomal degradation. Electron microscopy demonstrated that SUMO-1 was located on the 10-nm fibrils of NIs. In cultured PC12 cells, we found that inhibition of proteasome function by specific inhibitors resulted in the appearance of SUMO-1-immunopositive nuclear inclusions. Our study suggests that recruitment of SUMO-1 modified proteins into insoluble nuclear inclusions and proteasomal dysfunction may be involved in the pathogenesis of NIs in familial NIID cases.
Subject(s)
Cell Nucleus/metabolism , Cell Nucleus/pathology , Inclusion Bodies/metabolism , Inclusion Bodies/pathology , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/pathology , SUMO-1 Protein/metabolism , Adult , Aged , Animals , Biomarkers , Blotting, Western , Brain/pathology , Cysteine Endopeptidases/metabolism , Electrophoresis, Polyacrylamide Gel , Female , Humans , Immunohistochemistry , Microscopy, Electron , Middle Aged , Multienzyme Complexes/metabolism , Neurodegenerative Diseases/genetics , PC12 Cells , Pedigree , Proteasome Endopeptidase Complex , Rats , SUMO-1 Protein/geneticsABSTRACT
Genetic and protein studies have indicated abnormalities in alpha-synuclein in neurodegenerative diseases. However, the developmental localization and cellular role of synuclein isoforms is contentious. We investigated the cellular localization of alpha-, beta-, and gamma-synuclein in developing cultured rat neurons and following axonal transection of relatively mature neurons, a model that disrupts the axonal cytoskeleton and results in regenerative sprouting. Cortical neurons were grown up to 21 days in vitro (DIV). Axon bundles at 21 DIV were transected and cellular changes examined at 4 and 24 h post-injury. Immunohistochemistry demonstrated that alpha- and beta-synuclein were localized to cellular cytosol and growth cones at 3DIV, with accumulating puncta-like labeling within axons and growth cones by 10-21DIV. In contrast, gamma-synuclein immunoreactivity was limited at all time points. By 21DIV, alpha- and beta-synuclein were present in the same neurons but largely in separate subregions, only 26% of puncta contained both alpha- and beta-synuclein immunoreactivity. Less than 20% of alpha-, beta-, and pan-synuclein immunoreactive puncta directly colocalized to synaptophysin profiles at 10DIV, decreasing to 10% at 21DIV. Both alpha- and beta-synuclein accumulated substantially within damaged axons at 21DIV and were localized to cytoskeletal abnormalities. At latter time points post-injury, alpha- and beta-synuclein immunoreactive puncta were localized to growth cone-like structures in regenerating neurites. This study shows that alpha- and beta-synuclein have a precise localization within cortical neurons and are generally nonoverlapping in their distribution within individual neurons. In addition, synuclein proteins accumulate rapidly in damaged axons and may have a role in regenerative sprouting.
Subject(s)
Axons/physiology , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Animals , Axotomy , Cell Differentiation/physiology , Cell Division/physiology , Cells, Cultured , Cerebral Cortex/cytology , Cerebral Cortex/embryology , Cytosol/metabolism , Growth Cones/metabolism , Neurons/cytology , Protein Isoforms/metabolism , Rats , Rats, Wistar , Synaptophysin/metabolism , Synucleins , Time Factors , alpha-Synuclein , beta-Synuclein , gamma-SynucleinABSTRACT
The progressive, neurodegenerative process underlying idiopathic Parkinson's disease is associated with the formation of proteinaceous inclusion bodies that involve a few susceptible neuronal types of the human nervous system. In the lower brain stem, the process begins in the dorsal motor nucleus of the vagus nerve and advances from there essentially upwards through susceptible regions of the medulla oblongata, pontine tegmentum, midbrain, and basal forebrain until it reaches the cerebral cortex. With time, multiple components of the autonomic, limbic, and motor systems become severely impaired. All of the vulnerable subcortical grays and cortical areas are closely interconnected. Incidental cases of idiopathic Parkinson's disease may show involvement of both the enteric nervous system and the dorsal motor nucleus of the vagus nerve. This observation, combined with the working hypothesis that the stereotypic topographic expansion pattern of the lesions may resemble that of a falling row of dominos, prompts the question whether the disorder might originate outside of the central nervous system, caused by a yet unidentified pathogen that is capable of passing the mucosal barrier of the gastrointestinal tract and, via postganglionic enteric neurons, entering the central nervous system along unmyelinated praeganglionic fibers generated from the visceromotor projection cells of the vagus nerve. By way of retrograde axonal and transneuronal transport, such a causative pathogen could reach selectively vulnerable subcortical nuclei and, unimpeded, gain access to the cerebral cortex. The here hypothesized mechanism offers one possible explanation for the sequential and apparently uninterrupted manner in which vulnerable brain regions, subcortical grays and cortical areas become involved in idiopathic Parkinson's disease.
Subject(s)
Brain/pathology , Neurons/pathology , Parkinson Disease/etiology , Parkinson Disease/pathology , Vagus Nerve/pathology , Brain Stem/pathology , Disease Progression , Humans , Neural Pathways/pathology , Parkinson Disease/therapy , Severity of Illness IndexABSTRACT
Multiple system atrophy (MSA) belongs to synucleinopathies and is characterized pathologically by oligodendroglial inclusions (GCIs) composed of 20- to 30-nm tubular filaments. alpha-Synuclein fibrils formed in vitro, however, range between 10 and 12 nm in diameter. To understand the relationship between alpha-synuclein and GCI filaments, we conducted structural analyses of GCIs in fixed brain sections and isolated from fresh-frozen MSA brains. In fixed brain sections, GCIs were composed of amorphous material-coated filaments up to 30 nm in size. The filaments were often organized in parallel bundles extending into oligodendroglial processes. In freshly isolated GCIs, progressive buffer washes removed amorphous material and revealed that GCI filaments consisted of 10-nm-sized central core fibrils that were strongly alpha-synuclein immunoreactive. Image analysis revealed that each core fibril was made of two subfibrils, and each subfibril was made of a string of 3- to 6-nm-sized particles probably alpha-synuclein oligomers. Immunogold labeling demonstrated that epitopes encompassing entire alpha-synuclein molecule were represented in the core fibrils, with the N-terminal 11-26 and C-terminal 108-131 amino acid residues most accessible to antibodies, probably exposed on the surface of the fibril. Our study indicates that GCI filaments are multilayered in structure, with alpha-synuclein oligomers forming the central core fibrils of the filaments.
Subject(s)
Inclusion Bodies/pathology , Multiple System Atrophy/pathology , Nerve Tissue Proteins/ultrastructure , Oligodendroglia/pathology , Aged , Humans , Image Processing, Computer-Assisted , Inclusion Bodies/metabolism , Inclusion Bodies/ultrastructure , Microscopy, Immunoelectron , Middle Aged , Nerve Tissue Proteins/metabolism , Oligodendroglia/metabolism , Oligodendroglia/ultrastructure , Synucleins , alpha-SynucleinABSTRACT
Advanced silver stains and immunohistochemical reactions against alpha-synuclein were used to detect Parkinson's disease-related cytoskeletal abnormalities in select lower brain stem nuclei. Various types of inclusion bodies including inconspicuous and heretofore unnoted granular particles and thread-like Lewy neurites were visualized. Of the nuclei investigated (gigantocellular reticular nucleus, bulbar raphe nuclei, coeruleus-subcoeruleus area), only lipofuscin- or neuromelanin-laden neuronal types showed a propensity to develop the pathological changes. Neuronal types devoid of pigment deposits remained free of the cytoskeletal abnormalities. Fine, dust-like particles and small globular Lewy bodies were encountered solely within the limits of intraneuronal lipofuscin or neuromelanin deposits.
Subject(s)
Inclusion Bodies/pathology , Nerve Tissue Proteins/metabolism , Neurons/pathology , Parkinson Disease/pathology , Rhombencephalon/pathology , Aged , Cytoskeleton/metabolism , Cytoskeleton/pathology , Female , Humans , Inclusion Bodies/metabolism , Lewy Bodies/metabolism , Lewy Bodies/pathology , Lipofuscin/metabolism , Locus Coeruleus/metabolism , Locus Coeruleus/pathology , Locus Coeruleus/physiopathology , Male , Middle Aged , Neurites/metabolism , Neurites/pathology , Neurons/metabolism , Parkinson Disease/metabolism , Parkinson Disease/physiopathology , Pigmentation/physiology , Raphe Nuclei/metabolism , Raphe Nuclei/pathology , Raphe Nuclei/physiopathology , Reticular Formation/metabolism , Reticular Formation/pathology , Reticular Formation/physiopathology , Rhombencephalon/metabolism , Rhombencephalon/physiopathology , Synucleins , alpha-SynucleinABSTRACT
We report a case in which typical clinical features of idiopathic Parkinson's disease existed for seven years prior to the development of significant behavioral and cognitive changes and severe dementia. The patient presented with right-sided resting tremor, bradykinesia, and rigidity, which were highly responsive to levodopa. Serial neuropsychological evaluation revealed no evidence of dementia until late in the disease. The patient deteriorated rapidly eight years into the disease, requiring full care. She died 16 years after symptom onset and post-mortem neuropathological analysis revealed Lewy body Parkinson's disease and Pick's disease. To our knowledge, this is the first non-familial case with this combination of clinical history and pathologically confirmed disease to be reported in the literature. The absence of a family history of any neurological disease sets this case apart from the recently described genetic cases of frontotemporal dementia with Parkinsonism linked to chromosome 17. In addition, the relatively late onset of dementia in frontotemporal dementia is atypical. While there is considerable debate regarding the cause of dementia in idiopathic Parkinson's disease, our case illustrates that Pick's disease is one such cause.
Subject(s)
Parkinson Disease/complications , Pick Disease of the Brain/complications , Activities of Daily Living , Age Factors , Aphasia/diagnosis , Aphasia/etiology , Atrophy/pathology , Brain/metabolism , Brain/pathology , Cognition Disorders/diagnosis , Disability Evaluation , Fatal Outcome , Female , Follow-Up Studies , Humans , Immunohistochemistry , Lewy Bodies/metabolism , Lewy Bodies/pathology , Mental Disorders/diagnosis , Mental Disorders/etiology , Middle Aged , Nerve Tissue Proteins/metabolism , Neuropsychological Tests , Parkinson Disease/diagnosis , Pick Disease of the Brain/diagnosis , Reaction Time , Severity of Illness Index , Synucleins , tau Proteins/metabolismABSTRACT
Intracellular inclusions containing alpha-synuclein (alpha SN) are pathognomonic features of several neurodegenerative disorders. Inclusions occur in oligodendrocytes in multiple system atrophy (MSA) and in neurons in dementia with Lewy bodies (DLB) and Parkinson's disease (PD). In order to identify disease-associated changes of alpha SN, this study compared the levels, solubility and molecular weight species of alpha SN in brain homogenates from MSA, DLB, PD and normal aged controls. In DLB and PD, substantial amounts of detergent-soluble and detergent-insoluble alpha SN were detected compared with controls in grey matter homogenate. Compared with controls, MSA cases had significantly higher levels of alpha SN in the detergent-soluble fraction of brain samples from pons and white matter but detergent-insoluble alpha SN was not detected. There was an inverse correlation between buffered saline-soluble and detergent-soluble levels of alpha SN in individual MSA cases suggesting a transition towards insolubility in disease. The differences in solubility of alpha SN between grey and white matter in disease may result from different processing of alpha SN in neurons compared with oligodendrocytes. Highly insoluble alpha SN is not involved in the pathogenesis of MSA. It is therefore possible that buffered saline-soluble or detergent-soluble forms of alpha SN are involved in the pathogenesis of other alpha SN-related diseases.
Subject(s)
Lewy Body Disease/metabolism , Multiple System Atrophy/metabolism , Nerve Tissue Proteins/analysis , Nerve Tissue Proteins/metabolism , Parkinson Disease/metabolism , Aged , Blotting, Western , Brain Chemistry , Cerebellum/chemistry , Electrophoresis, Polyacrylamide Gel , Frontal Lobe/chemistry , Humans , Middle Aged , Molecular Weight , Multiple System Atrophy/etiology , Myelin Sheath/chemistry , Myelin Sheath/ultrastructure , Neurons/chemistry , Oligodendroglia/chemistry , Pons/chemistry , Reference Values , Sodium Dodecyl Sulfate/chemistry , Solubility , Synucleins , alpha-SynucleinABSTRACT
alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies. We examined the relationship between alpha-synuclein, ubiquitin, and lipids in Lewy bodies of fixed brain sections or isolated from cortical tissues of dementia with Lewy bodies. Lewy bodies exhibited a range of labeling patterns for alpha-synuclein and ubiquitin, from a homogeneous pattern in which alpha-synuclein and ubiquitin were evenly distributed and overlapped across the inclusion body to a concentric pattern in which alpha-synuclein and ubiquitin were partially segregated, with alpha-synuclein labeling concentrated in the peripheral domain and ubiquitin in the central domain of the Lewy body. Lipids represented a significant component in both homogeneous and concentric Lewy bodies. These results suggest that Lewy bodies are heterogeneous in their subregional composition. The segregation of alpha-synuclein to Lewy body peripheral domain is consistent with the hypothesis that alpha-synuclein is continually deposited onto Lewy bodies.
Subject(s)
Lewy Bodies/chemistry , Lewy Body Disease/pathology , Lipids/analysis , Nerve Tissue Proteins/analysis , Ubiquitins/analysis , Aged , Aged, 80 and over , Brain/pathology , Brain Chemistry , Female , Humans , In Vitro Techniques , Lewy Bodies/pathology , Lewy Bodies/ultrastructure , Male , Microscopy, Immunoelectron , Middle Aged , Neurons/chemistry , Neurons/pathology , Neurons/ultrastructure , Parkinson Disease/pathology , Synucleins , alpha-SynucleinABSTRACT
Pathological changes which consistently develop in the lower brain stem of patients suffering from Parkinson's disease are described against the background of the internal organization and interconnections of the involved nuclei, i.e., the gigantocellular reticular nucleus, bulbar raphe nuclei, and coeruleus-subcoeruleus area. Immunoreactions against the presynaptic protein alpha-synuclein reveal not only the voluminous forms of Lewy bodies and Lewy neurites but also the otherwise inconspicuous dot- or thread-like types. These lesions develop solely in specific neuronal types. Lipofuscin- or neuromelanin-laden projection cells which at the same time generate a long, unmyelinated or sparsely myelinated axon are particularly susceptible to developing the changes. The bulbar nuclei under consideration receive strong input from supramedullary sources, above all from higher order centers of the limbic system such as the central amygdalar nucleus, periaqueductal gray, and parabrachial nuclei. In turn, they generate descending projections to premotor and motor neurons of the somatomotor system. The disease-related deterioration of both the supramedullary limbic centers and the bulbar brain stem nuclei reduces the limbic influence and markedly impairs the control of premotor and motor neurons. This functional deficit most probably contributes to the overall dysfunction of the motor system typically evolving in the course of Parkinson's disease.
Subject(s)
Limbic System/pathology , Motor Neurons/pathology , Parkinson Disease/pathology , Reticular Formation/pathology , Aged , Female , Humans , Limbic System/physiology , Locus Coeruleus/pathology , Locus Coeruleus/physiology , Male , Motor Neurons/chemistry , Nerve Tissue Proteins/analysis , Parkinson Disease/physiopathology , Raphe Nuclei/pathology , Raphe Nuclei/physiology , Reticular Formation/physiology , Synucleins , alpha-SynucleinABSTRACT
Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.
Subject(s)
Cerebral Cortex/metabolism , Lewy Bodies/metabolism , Microtubule-Associated Proteins/metabolism , Nerve Tissue Proteins/metabolism , Aged , Aged, 80 and over , Cell Fractionation , Cerebral Cortex/chemistry , Female , Humans , Immunomagnetic Separation , Lewy Bodies/chemistry , Lewy Bodies/ultrastructure , Male , Microscopy, Immunoelectron , Microtubule-Associated Proteins/analysis , Nerve Tissue Proteins/analysis , Neurites/metabolism , Neurites/ultrastructure , Phosphoproteins/metabolism , Protein Binding , Recombinant Proteins/metabolism , Recombinant Proteins/ultrastructure , Synucleins , alpha-SynucleinABSTRACT
It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.
Subject(s)
Neocortex/chemistry , Nerve Tissue Proteins/analysis , Presynaptic Terminals/chemistry , Thalamus/chemistry , Adult , Aged , Aged, 80 and over , Antibodies , Female , Humans , Male , Middle Aged , Nerve Tissue Proteins/immunology , Parkinson Disease/pathology , Synucleins , alpha-SynucleinABSTRACT
Immunohistochemical studies have shown that oligodendroglial inclusions in multiple system atrophy contain alpha-synuclein, a synaptic protein also found in Lewy bodies in Parkinson's disease. We have now used density gradient enrichment and an anti-alpha-synuclein immunomagnetic technique to isolate pure and morphologically intact oligodendroglial inclusions from brain white matter of patients dying with multiple system atrophy. Filamentous inclusion structures were obtained only from multiple system atrophy tissue, but not from normal brain tissues, or from multiple system atrophy tissue processed without anti-alpha-synuclein antibody. We confirmed the purity and morphology of isolated inclusions by electron microscopy. The inclusions comprised multiple protein bands after separation by polyacrylamide gel electrophoresis. Immunoblotting demonstrated that these proteins included alpha-synuclein, alphaB-crystallin, tubulins, ubiquitin, and prominent, possibly truncated alpha-synuclein species as high-molecular-weight aggregates. Our study provides the first biochemical evidence that oligodendroglial inclusion filaments consist of multiple protein components, suggesting that these inclusions may form as a result of multiprotein interactions with alpha-synuclein.